Presentation is loading. Please wait.

Presentation is loading. Please wait.

Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142.

Published byCora Summers Modified over 9 years ago

Similar presentations

Presentation on theme: "Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142."— Presentation transcript:

1 Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142

2 Characteristics of cancer-associated adverse event reports Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142

3 (A) Rates of cancer adverse event reports in patients treated with the combination ezetimibe/simvastatin and other potent cholesterol-lowering drugs (B) The proportion of cancer adverse event reports relative to all reported adverse events in patients treated with the combination ezetimibe/simvastatin and other potent cholesterol lowering drugs *P<.01 versus ezetimibe/simvastatin. †P<.01 versus ezetimibe Alsheikh-Ali AA, Karas RH. J Clin Lip 2009;3:138-142

4 Rates of cancer associated adverse event reports in patients treated with the combination ezetimibe/simvastatin (E/S) and other potent cholesterol lowering drugs (rate per million prescriptions) Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142

Download ppt "Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142."

Similar presentations

Clinical Effectiveness Dr. Shahram Yazdani Associate Professor of SBUMS.

Clinical Effectiveness Dr. Shahram Yazdani Associate Professor of SBUMS.
Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165: 2264-2271.

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)

Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)
STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.

STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.
What’s the point of Ezetimibe? MeReC dio/cdlipids/merec_extra_no47.html.

What’s the point of Ezetimibe? MeReC dio/cdlipids/merec_extra_no47.html.
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.

High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.
Pharmacogenetics.

Pharmacogenetics.
4S: Scandinavian Simvastatin Survival Study

4S: Scandinavian Simvastatin Survival Study
Demographic Characteristics of Individuals With AERS of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure (COMPOSITE AERS) Alsheikh-Ali AA et al.

Demographic Characteristics of Individuals With AERS of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure (COMPOSITE AERS) Alsheikh-Ali AA et al.
Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:587-92.

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:
Alcohol, Other Drugs, and Health: Current Evidence

Alcohol, Other Drugs, and Health: Current Evidence
Rates of Ambulatory Care Visits for Treating Adverse Drug Events (VADEs): Trend 1995–2001 Data: National Ambulatory Medical Care Survey and National Hospital.

Rates of Ambulatory Care Visits for Treating Adverse Drug Events (VADEs): Trend 1995–2001 Data: National Ambulatory Medical Care Survey and National Hospital.
Cost-Sharing for Plans Offered in the Federal Marketplace for 2018

Cost-Sharing for Plans Offered in the Federal Marketplace for 2018
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Similar presentations

Ads by Google